Whitehawk Therapeutics is a clinical-stage oncology therapeutics company focused on developing and commercializing next-generation antibody drug conjugates (ADCs). The company's portfolio consists of three in-licensed ADC assets targeting the tumor antigens PTK7, MUC16, and SEZ6, which are designed to deliver a Topoisomerase I inhibitor payload to cancer cells. These assets, known as HWK-007, HWK-016, and HWK-206, are intended for the treatment of solid tumors including non-small cell lung cancer, ovarian cancer, endometrial cancer, small cell lung cancer, and neuroendocrine tumors. Whitehawk entered into an intellectual property license agreement with WuXi Biologics in December 2024 for the global development and commercialization of this portfolio, which utilizes the CPT113 linker-payload platform originally developed by Hangzhou DAC Biotechnology. The company previously operated the FYARRO business, involving the commercialization of nab-sirolimus for advanced malignant PEComa, but divested this asset to KAKEN Investments in March 2025. Whitehawk utilizes an outsourced model for research, development, and manufacturing, partnering with CRDMOs such as WuXi Biologics to advance its clinical trials.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage ir.whitehawktx.com
Sector Healthcare IR page ir.whitehawktx.com
Tags
oncology, antibody drug conjugates, solid tumors, lung cancer, ovarian cancer, neuroendocrine tumors, drug delivery, clinical-stage, topoisomerase inhibitor, HWK-007, HWK-016, HWK-206, FYARRO, nab-sirolimus, CPT113, WuXi Biologics, Hangzhou DAC Biotechnology, KAKEN Investments, Aadi Subsidiary
Press page —

Metrics

Valuation  
Market cap $ 221.874M
Market cap (USD) $ 221.874M
P/E -1.99
PEG —
P/BV 1.36
P/S 31.05
P/OCF -3.01
P/FCF -3.01
Dividend yield —
Turnover / mcap —
Returns  
ROE -21.8%
ROI -20.9%
ROIC -86.9%
Profit margin -288.3%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 27
Quality score -70.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008
Revenue 7.145M 25.983M 24.354M 15.216M 1.12M 15M — 20.157M — — — — — — — — — —
Net profit -20.596M -63.691M -65.765M -60.513M -110.09M -4.315M -23.271M -10.397M -21.401M -39.434K -31.44K -30.799K -28.701K -27.365K -27.185K -22.395K — —
Free cash flow -97.985M -61.204M -63.635M -50.084M -22.469M -5.404M -24.089M -5.846M -18.892M — — — — — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008
Share price 2.42 3.16 2.02 12.83 24.15 — — — — — — — — — — — — —
Price performance 12m -0.23 0.56 -0.84 -0.47 — — — — — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 4,157 — — — 14.1M 0.00 1.86M 5.49M 5.9M 0.00
↳ YoY growth -100.0% +194.7% +7.6% -100.0%
Lease liabilities (USD) — — — 169,993 67,438 605,000 1.66M 1.27M 833,000 0.00
Cash and deposits (USD) 4,012 20.3M 62.6M 38.5M 42.6M 149M 39M 62.9M 28.7M 37.6M
Intangible assets (USD) — — — — 0.00 3.81M 0.00 — — —
Right-of-use assets (USD) — — — 162,124 63,919 557,000 1.52M 1.17M 787,000 0.00
Cash flow detail
Operating cash flow (USD) -24,517 -18.9M -5.81M -23.9M -5.38M -22.4M -49.6M -59.7M -59.6M -97.4M
Purchases of property, plant and equipment (USD) -113,297 -8,896 -37,912 -236,952 -19,025 -46,000 -444,000 -3.97M -1.65M -552,000
Change in receivables (cash effect) (USD) 114,359 4,157 — — -13.9M 14.1M -1.86M -3.63M -415,000 -1M
Change in inventories (cash effect) (USD) — — — — — 0.00 -1.86M -3.27M 1.12M 170,000
Change in payables (cash effect) (USD) 600 1.6M 1.86M -2.22M -1.44M 8.29M 3.22M -132,000 -9.77M 3.92M
Dividends paid (cash effect) (USD) — — — — — -4.41M 0.00 — — —
Interest paid (cash effect) (USD) — — — — — -22,000 -230,000 -230,000 -211,000 0.00
Share-based compensation (USD) 488,326 649,409 3.43M 1.09M 1.28M 2.11M 9.64M 12M 10.8M 9.87M
Operating cash flow before change in receivables (USD) -15.8M -18.9M — — 1.16M -36.6M -47.8M -56M -59.1M -96.4M
Free cash flow (OCF - PPE - intangibles) (USD) -15.8M -18.9M -5.85M -24.1M -5.4M -22.5M -50.1M -63.6M -61.2M -98M
Income detail
Research and development expense (USD) 11.4M 12.1M 17.9M 12.8M 12.6M 19.7M 32.7M 48.9M 51M 91M
↳ 5y CAGR +11.6% +21.9% +22.3% +31.8% +48.5%
Total comprehensive income (USD) — — — — -4.47M -111M -60.6M -65.6M -63.7M -20.5M
Comprehensive income to owners (USD) — — — — -4.47M -111M -60.6M -65.6M -63.7M -20.5M
Reported Mar 15, 2018 Mar 7, 2019 Mar 7, 2019 Mar 16, 2020 Mar 17, 2022 Mar 29, 2023 Mar 29, 2023 Mar 13, 2024 Mar 28, 2025 Mar 12, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Initiated Phase 1 trial for HWK-206 in the U.S., the third Whitehawk program to enter the clinic in the last 12 months; HWK-206 received Fast Track designation from the FDA

Cash, cash equivalents and short-term investments of $169.7 million as of September 30, 2026, anticipated to fund operations into 2H 2028

MORRISTOWN, NJ, November 9, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody drug conjugate (ADC) cancer treatments, today announced financial results for the quarter ended September 30, 2026, and provided recent corporate highlights.

“We continue to dose escalate patients in our Phase 1 programs for HWK-007 and HWK-016 and remain on track to report initial data in the first half of 2027,” said Dave Lennon, PhD, President and Chief Executive Officer of Whitehawk Therapeutics. “We also initiated the Phase 1 trial of HWK-206, marking the advancement of all three of our original ADC programs into clinical development within the last 12 months.

10/01/26

PDF Version

MUC16 Expression Remained High and Stable Following Standard-of-Care Therapies, Supporting Its Potential Utility in Both Combination Approaches and Relapsed Settings

High MUC16 Expression Was Associated with Poor Real-World Overall Survival in High-Grade Serous Ovarian Carcinoma, the Most Common Subtype of Ovarian Cancer

Findings Reinforce the Scientific Rationale for HWK-016, Whitehawk's Next-Generation MUC16-Directed ADC Currently in Phase 1 Development

MORRISTOWN, N.J., Oct. 1, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody drug conjugate (ADC) cancer treatments, today announced the presentation of two real-world analyses supporting mucin 16 (MUC16) as a durable therapeutic target and potential prognostic biomarker in ovarian cancer. These data will be presented at the International Gynecologic Cancer Society (IGCS) Annual Global Meeting taking place October 1-3, 2026, in Montreal, Canada.

In tumor samples from patients with ovarian cancer, MUC16 expression remained high and largely stable following standard-of-care (SoC) treatments, including platinum and non-platinum chemotherapy, bevacizumab-containing regimens, PARP inhibitors and mirvetuximab soravtansine. Treatment-associated changes in MUC16 expression were consistently small, and MUC16 demonstrated less treatment-associated variation than several other ADC targets, including FRα, TROP2 and NaPi2b. These findings suggest MUC16 is a durable therapeutic target for ADCs across multiple lines of therapy, and support development strategies that include both combination approaches and treatment in relapsed disease.

"For an ADC target to have broad clinical utility in ovarian cancer, it's important that it remains consistently expressed as patients move through multiple lines of therapy," said Margaret Dugan, MD, Chief Medical Officer of Whitehawk Therapeutics. "These findings suggest MUC16 is durable throughout the treatment continuum and support the exploration of HWK-016 both in combination with established therapies and in patients whose disease has progressed following prior treatment."

In a separate analysis of patients with high-grade serous ovarian carcinoma (HGSOC) – the most common histologic subtype accounting for approximately 70% of cases – high tumor MUC16 expression was prognostically associated with poor real-world overall survival (rwOS). This association remained statistically significant after adjustment for key clinical and molecular covariates and was also observed among patients who were treatment-naïve at first metastatic diagnosis.

"Ovarian cancer continues to be a difficult-to-treat disease with new therapeutic approaches urgently needed," said Robert L. Coleman, MD, Texas Oncology. "The observation that high MUC16 expression was independently associated with poorer real-world overall survival indicates it is an important marker of more aggressive disease biology, and supports the continued investigation of MUC16-directed ADCs in this disease."

Poster Details:

Title: Durable and Treatment-Agnostic MUC16 Expression in Ovarian Cancer Supports Targeted Antibody-Drug Conjugate Development Poster: 950 Presenter: Kathleen N. Moore, MD, University of Nebraska Medical Center, Omaha, Nebraska Date & Time: E-Poster

Key Findings:

  • MUC16 expression remained largely stable following platinum and non-platinum chemotherapy, bevacizumab-containing regimens, PARP inhibitors and mirvetuximab soravtansine.

  • Findings suggest that the target may be suitable for MUC16-directed therapy after prior SoC treatment and in combination with standard early-line platinum-based treatment.

  • Stable MUC16 expression is also observed in paired tumor samples.

  • MUC16 demonstrated less treatment-associated variation than several late-stage ADC targets, including FRα, TROP2 and NaPi2b.

Title: High MUC16 Expression Is Associated With Poor Real-World Overall Survival in Patients With High-Grade Serous Ovarian Carcinoma **Poster:**519 Presenter: Robert L. Coleman, MD, Texas Oncology, The Woodlands, Texas Date & Time: October 1, 2026, 2:35-2:40 ET

Key Findings:

  • MUC16 expression at metastatic diagnosis was prognostically associated with poor rwOS.

  • Results were similar in the treatment-naïve subpopulation.

  • Eastern Cooperative Oncology Group performance status, BRCA mutation status and age at diagnosis were also independent prognostic factors of rwOS.

  • High circulating CA125 was also associated with poor prognosis in patients with heavily pretreated HGSOC.

HWK‑016 is a MUC16-directed, next-generation ADC targeting the non-shed extracellular domain that is being evaluated in an ongoing Phase 1 clinical trial in patients with advanced ovarian and endometrial cancers (NCT07470853).

These analyses were conducted as part of a previously announced collaboration between Whitehawk and Tempus AI. The posters will be accessible on the Presentations page of the Investors & News section of the Company's website at www.whitehawktx.com.

About Whitehawk TherapeuticsWhitehawk Therapeutics is a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody drug conjugate (ADC) cancer treatments. Whitehawk's portfolio includes HWK-007, HWK-016 and HWK-206, ADCs engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement.

Whitehawk's underlying ADC platform leverages CPT113 as the core linker-payload technology, enhanced with its proprietary Carbon Bridge Cysteine Re-pairing (CBCR) bioconjugation process to support improved stability and therapeutic index. More information on the Company is available at www.whitehawktx.com and connect with us on LinkedIn. Any references to the Company's website or other online resources are provided solely for convenience and are not incorporated by reference into this press release. Investors should rely only on the information contained in this press release and the Company's filings with the Securities and Exchange Commission.

Forward-Looking StatementsThis press release contains certain forward-looking statements regarding the business of Whitehawk Therapeutics that are not a description of historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the Company's current beliefs and expectations and may include, but are not limited to, statements relating to the potential therapeutic value and market opportunity for HWK-016 and expectations regarding the beneficial characteristics, design features and the potential targeted markets with respect to HWK-016. Actual results could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, uncertainties associated with preclinical and clinical development of HWK-016.

Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, including under the caption "Item 1A. Risk Factors," and in Whitehawk's subsequent Quarterly Reports on Form 10-Q, and elsewhere in Whitehawk's reports and other documents that Whitehawk has filed, or will file, with the SEC from time to time and available at www.sec.gov.

All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Whitehawk undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This cautionary statement is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

09/13/26

PDF Version

PTK7 Expression Remained Stable Following Standard-of-Care Therapies, Supporting Its Relevance as a Target in Second- or Later-Line EGFR NSCLC

Findings Reinforce the Scientific Rationale for HWK-007, Whitehawk's Next-Generation PTK7-Directed ADC Currently in Phase 1 Development

MORRISTOWN, N.J., Sept. 13, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody drug conjugate (ADC) cancer treatments, today announced the presentation of two real-world analyses supporting protein tyrosine kinase 7 (PTK7) as a durable and clinically relevant ADC target in patients with pretreated, EGFR wild-type non-small cell lung cancer (NSCLC). The data will be presented at the IASLC 2026 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer, taking place September 12-15, 2026, in Seoul, Republic of Korea.

Whitehawk Therapeutics, Inc. logo

In tumor samples from patients with EGFR wild-type lung adenocarcinoma, PTK7 expression remained largely stable following standard-of-care (SoC) treatments, including chemotherapy and immunotherapy, and demonstrated less treatment associated variation than several other ADC targets in late-stage development. PTK7 expression was also generally consistent regardless of the presence or absence of other actionable genomic alterations (AGA). These findings indicate PTK7 remains available for targeted ADCs for patients that have progressed through multiple lines of SoC therapy and across clinically relevant subgroups.

A separate analysis of patients with advanced EGFR wild-type lung adenocarcinoma found that real-world overall survival was not impacted based on PTK7-expression, supporting PTK7 as a target-engagement biomarker for ADC payload delivery independent of prognosis in NSCLC.

"The development strategy for our PTK7-directed ADC, HWK-007, is grounded in understanding not only where PTK7 is expressed, but also how that expression behaves in a real-world treatment setting," said Margaret Dugan, MD, Chief Medical Officer of Whitehawk Therapeutics. "The stability of PTK7 expression after standard of care therapies, in particular compared to other therapies in late-stage development, add important translational context as we evaluate HWK-007 in patients with EGFR wild-type NSCLC."

Key Findings:

Durable and Treatment-Agnostic PTK7 Expression in EGFR Wild-Type Lung Adenocarcinoma Supports Targeted ADC Development

  • PTK7 expression remained largely stable following standard-of-care immunotherapy, chemotherapy, chemoimmunotherapy and tyrosine kinase inhibitor treatment, suggesting that the target may remain available for PTK7-directed therapy after prior treatment.

  • Stable PTK7 expression is also observed in paired tumor samples.

  • PTK7 demonstrated less treatment-associated variation than several late-stage ADC targets, including MET, PD-L1 and ITGB6.

  • PTK7 expression was generally consistent across tumors with or without other AGA, including KRAS G12C, ALK and MET alterations, suggesting relevance of PTK7 as an ADC target across both AGA+ and AGA- NSCLC subgroups.

Association Between PTK7 Expression and Real-World Survival in Pretreated Patients With EGFR Wild-Type Lung Adenocarcinoma

  • PTK7 expression was not independently associated with real-world overall survival or progression-free survival in patients with advanced EGFR wild-type lung adenocarcinoma receiving second- or later-line therapy, supporting PTK7 as a target-engagement biomarker rather than a marker of prognosis.

  • Clinical outcomes were driven primarily by established prognostic factors, including Eastern Cooperative Oncology Group performance status and extent of prior therapy.

  • PTK7-low tumors were enriched for KEAP1 and STK11 alterations, suggesting biological heterogeneity of EGFR wild-type NSCLC.

"Understanding whether a therapeutic target remains present after prior treatment is particularly important in advanced lung cancer, where patients often receive multiple lines of therapy," said Aaron E. Lisberg, MD, Associate Professor of Medicine at the David Geffen School of Medicine at UCLA. "The stability of PTK7 expression across standard treatments and clinically relevant molecular subgroups supports further investigation of PTK7-directed ADCs in patients with previously treated EGFR wild-type lung adenocarcinoma."

Poster Presentation Details:

Title: Durable and Treatment-Agnostic PTK7 Expression in EGFR Wild-Type Lung Adenocarcinoma Supports Targeted ADC Development Poster: P2.241 Presenter: Aaron E. Lisberg, MD, University of California Los Angeles, Los Angeles, CA, USA Date & Time: Monday, September 14, 2026, at 10:30 AM KST

Title: Association Between PTK7 Expression and Real-World Survival in Pretreated Patients With EGFR Wild-Type Lung Adenocarcinoma **Poster:**P2.147 Presenter: Grace Dy, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA Date & Time: Monday, September 14, 2026, at 10:30 AM KST

HWK‑007 is PTK7-directed, next-generation ADC being evaluated in an ongoing Phase 1 clinical trial in patients with non-squamous, EGFR wild-type NSCLC, platinum-resistant ovarian cancer and endometrial cancer (NCT07444814).

These analyses were conducted as part of a previously announced collaboration between Whitehawk and Tempus AI. The posters will be accessible on the Presentations page of the Investors & News section of the Company's website at www.whitehawktx.com.

About Whitehawk TherapeuticsWhitehawk Therapeutics is a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved cancer treatments. Whitehawk's portfolio includes HWK-007, HWK-016 and HWK-206, ADCs engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement.

Whitehawk's underlying ADC platform leverages CPT113 as the core linker-payload technology, enhanced with its proprietary Carbon Bridge Cysteine Re-pairing (CBCR) bioconjugation process to support improved stability and therapeutic index. More information on the Company is available at www.whitehawktx.com and connect with us on LinkedIn. Any references to the Company's website or other online resources are provided solely for convenience and are not incorporated by reference into this press release. Investors should rely only on the information contained in this press release and the Company's filings with the Securities and Exchange Commission.

Forward-Looking StatementsThis press release contains certain forward-looking statements regarding the business of Whitehawk Therapeutics that are not a description of historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the Company's current beliefs and expectations and may include, but are not limited to, statements relating to the potential therapeutic value and market opportunity for HWK-007 and expectations regarding the beneficial characteristics, design features and the potential targeted markets with respect to HWK-007. Actual results could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, uncertainties associated with preclinical and clinical development of HWK-007 .

Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, including under the caption "Item 1A. Risk Factors," and in Whitehawk's subsequent Quarterly Reports on Form 10-Q, and elsewhere in Whitehawk's reports and other documents that Whitehawk has filed, or will file, with the SEC from time to time and available at www.sec.gov.

All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Whitehawk undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This cautionary statement is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Prompts

Whitehawk Therapeutics, Inc. (ticker WHWK), listed in United States.

Company History

Date Change Detail
Mar 26, 2025 Renamed AADI BIOSCIENCE, INC. → WHITEHAWK THERAPEUTICS, INC.
Aug 27, 2021 Renamed AERPIO PHARMACEUTICALS, INC. → AADI BIOSCIENCE, INC.
Mar 17, 2017 Renamed ZETA ACQUISITION CORP II → AERPIO PHARMACEUTICALS, INC.
— Former tickers AADI

ETFs Holding Whitehawk Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
AVSC 0.01% 62,719 $ 188.784K Nov 16, 2026
DFSU 0.00% 3,164 $ 9,713.48 Nov 12, 2026
DXUV 0.00% 3,330 $ 10.223K Nov 12, 2026
DFSV 0.00% 10,140 $ 31.13K Nov 12, 2026
DFAU 0.00% 3,560 $ 10.929K Nov 12, 2026
DFAT 0.00% 5,667 $ 17.354K Nov 12, 2026
DFAS 0.00% 3,021 $ 9,274.47 Nov 12, 2026